deCODE genetics was acquired by Amgen (NASDAQ: AMGN) in December 2012 to uncover risk factors and drug targets for dozens of serious diseases. The company had previously gone public in July 2000 (NASDAQ: DCGN).
| Headquarters | Reykjavik, Iceland |
deCODE genetics
